Literature DB >> 6743765

Biotransformation of urapidil: isolation and identification of metabolites in mouse, rat, dog and man.

E Sturm, K Zech.   

Abstract

The identification of biotransformation products of the new antihypertensive drug urapidil in mouse, rat, dog and man has been performed by means of high-performance liquid chromatographic and mass spectrometric techniques. In urine, three metabolites were found in addition to the unchanged drug. The para-hydroxylated product (1) (6-(3-[4-(o-methoxy-p-hydroxyphenyl)piperazinyl]-propylamino)-1, 3-dimethyl-uracil), the O-demethylated compound (2) (6-(3-[4-(o-hydroxyphenyl)piperazinyl]-propylamino)-1, 3-dimethyluracil) and the uracil-N-dealkylated compound (3) (6-(3-[4-(o-methoxyphenyl)piperazinyl]-propylamino)-1-methyluracil). In urine of dog, the metabolite with the N-oxide structure (5) was also identified, but only in trace amounts (6-(3-[4-(o-methoxyphenyl)piperazinyl-N-oxide]-propylamino)-1, 3-dimethyluracil).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743765     DOI: 10.1002/bms.1200110504

Source DB:  PubMed          Journal:  Biomed Mass Spectrom        ISSN: 0306-042X


  1 in total

Review 1.  Clinical pharmacokinetics of urapidil.

Authors:  R Kirsten; K Nelson; V W Steinijans; K Zech; R Haerlin
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.